Linezolid Fresenius Kabi (Linezolid)

Linezolid is an oxazolidinone antibiotic used for serious Gram‑positive bacterial infections.

• Skin and soft tissue infections: effective against Gram‑positive organisms including MRSA, reducing infection severity.
• Community‑acquired and hospital‑acquired pneumonia: provides bacteriostatic activity to improve clinical outcomes.
• Infections caused by Gram‑positive bacteria (e.g., MRSA): achieves bacterial eradication when other agents are unsuitable.

• Linezolid binds to the 50S subunit of bacterial ribosomes, preventing the formation of the initiation complex required for protein synthesis. This inhibition halts bacterial growth, rendering the organism unable to proliferate and allowing the host immune system to clear the infection.

Linezolid may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: watery stools occurring during therapy.
• Headache: transient cranial discomfort.
• Vomiting: occasional emesis.
• Metallic taste: altered taste perception.
• Anemia: reduction in red blood cell count.

Serious or Rare Side Effects

• Thrombocytopenia: significant drop in platelet count.
• Peripheral neuropathy: nerve damage presenting as tingling or numbness.
• Serotonin syndrome: potentially life‑threatening reaction when combined with serotonergic agents.
• Lactic acidosis: rare metabolic disturbance requiring immediate medical attention.
• Severe allergic reaction: rash, swelling, or anaphylaxis.

When prescribing Linezolid, clinicians should consider several safety measures.

• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic dysfunction: assess liver enzymes regularly.
• Concomitant serotonergic drugs: avoid to prevent serotonin syndrome.
• Myelosuppression: perform frequent blood count monitoring.
• Pregnancy: use only if potential benefits outweigh risks.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Linezolid interacts with several drug classes; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid)

• Selective serotonin reuptake inhibitors (SSRIs): risk of serotonin syndrome.
• Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome.
• Rifampin: reduces linezolid plasma concentrations.

Moderate Interactions (Monitor Closely)

• Warfarin: may increase INR and bleeding risk.
• Phenytoin: may lower linezolid effectiveness.
• NSAIDs: may enhance bleeding tendency.